Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPBWR1 | P48145 | 2/20 | 0.55 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.54 |
| ▸ | PRKACB | P22694 | 1/20 | 0.52 |
| ▸ | GHSR | Q92847 | 1/20 | 0.51 |
| ▸ | IL23R | Q5VWK5 | 5/20 | 0.50 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.50 |
| ▸ | NMBR | P28336 | 1/20 | 0.50 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.49 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.49 |
| ▸ | C5AR1 | P21730 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29641046 | 0.94 | GHSR (0.56) | PRKACBGHSRNMBR | |
| SCHEMBL30990571 | 0.94 | GHSR (0.56) | PRKACBGHSRNMBR | |
| SCHEMBL29511112 | 0.94 | GHSR (0.56) | PRKACBGHSRNMBR | |
| SCHEMBL29832285 | 0.94 | NPBWR1 (0.58) | NPBWR1PRMT1GHSRIL23ROPRM1 | |
| SCHEMBL29419491 | 0.94 | NPBWR1 (0.58) | NPBWR1PRMT1GHSRIL23ROPRM1 | |
| SCHEMBL29511125 | 0.93 | PRKACB (0.57) | NPBWR1PRKACBGHSRCXCR4NMBR | |
| SCHEMBL31593359 | 0.93 | GHSR (0.56) | NPBWR1PRKACBGHSRNMBR | |
| SCHEMBL29484173 | 0.93 | GHSR (0.56) | NPBWR1PRKACBGHSRNMBR | |
| SCHEMBL29790169 | 0.93 | GHSR (0.56) | NPBWR1PRKACBGHSRNMBR | |
| SCHEMBL29609768 | 0.93 | GHSR (0.56) | NPBWR1PRKACBGHSRNMBR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4605407-A2 | METHODS OF STIMULATING APPETITE AND/OR INCREASING BODY WEIGHT USING NON-NATURALLY OCCURRING MELANOCORTIN RECEPTOR ANTAGONIST ANALOGS | Endevica Bio, Inc. (US) | 2025-08-27 | — | — | EP | disclosed |
| WO-2025123055-A1 | NON-NATURALLY OCCURRING MELANOCORTIN ANALOGS AND ASSOCIATED METHODS FOR MODULATING WEIGHT GAIN | ENDEVICA BIO, INC. (US) | 2025-06-12 | — | — | WO | disclosed |
| WO-2025123056-A1 | NON-NATURALLY OCCURRING MELANOCORTIN ANALOGS AND ASSOCIATED METHODS | ENDEVICA BIO, INC. (US) | 2025-06-12 | — | — | WO | disclosed |
| US-20250129118-A1 | MELANOCORTIN 1 RECEPTOR LIGANDS AND METHODS OF USE | H LEE MOFFITT CANCER CT & RES (US) | 2025-04-24 | — | — | US | disclosed |
| WO-2024086381-A2 | METHODS OF STIMULATING APPETITE AND/OR INCREASING BODY WEIGHT USING NON-NATURALLY OCCURRING MELANOCORTIN RECEPTOR ANTAGONIST ANALOGS | ENDEVICA BIO, INC. (US) | 2024-04-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250129118-A1 | MELANOCORTIN 1 RECEPTOR LIGANDS AND METHODS OF USE | MC1R, MC3R, MC5R | NPBWR1 32/4885PRMT1 2038/4885PRKACB 2884/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.